Acambis Phase II vaccine data

Acambis (LSE:ACM; ACAM) said that in a U.S. Phase II trial of its ChimeriVax-JE vaccine to prevent Japanese encephalitis, 6 of 10 previously vaccinated patients responded with a rapid rise in neutrali...